Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MGA012 + MGD007
- Development stage
- Unknown
- Lead developer
- MacroGenics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MGA012 + MGD007 is a combination therapy being investigated for the treatment of relapsed or refractory metastatic colorectal carcinoma. This combination pairs two distinct therapeutic agents with complementary mechanisms of action. MGA012 (also known as INCMGA00012 or retifanlimab) is an anti-PD-1 antibody that works by blocking the PD-1 receptor, thereby enhancing T-cell immune responses against cancer cells. MGD007 is a humanized gpA33 × CD3 DART® (Dual-Affinity Re-Targeting) protein developed by MacroGenics. This bispecific T-cell engager works by simultaneously binding to: gpA33 (a surface antigen expressed on colorectal cancer cells) and CD3 (a T-cell surface glycoprotein). This dual binding mechanism redirects T cells to target and kill cancer cells expressing the gpA33 antigen.
- Brand names
- Zynyz
- Other names
- retifanlimab-dlwrMGA012MGA-012MGA 012MGD007MGD-007MGD 007
02
Targets
GPA33 (Glycoprotein A33)PDCD1 (Programmed cell death protein 1 receptor)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on MGA012 + MGD007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MGA012 + MGD007.